Dabigatran clinical trials
Dabigatran is named as an intervention in 11 current clinical trials in our Germany, Denmark, Canada, India, Sweden, Australia, China, France, USA, Spain, Italy, Netherlands, Switzerland, Brazil, South Korea and Norway registers. 8 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Population Health Research Institute (2). The most-studied condition is Stroke.
How Dabigatran works
All drug targets →- Thrombin inhibitor InhibitorTarget: F2 coagulation factor II, thrombin✓ In ChEMBL and the Guide to Pharmacology
- Paroxysmal atrial fibrillationPhase 3
- ThrombocytopeniaPhase 3
- Atrial fibrillationPhase 3
- Portal vein thrombosisPhase 2/3
- Cirrhosis of liverPhase 2/3
- ThromboembolismPhase 2
- Heart failurePhase 2
- HemorrhagePhase 2
- Ischemic strokePhase 2
- Transient ischemic attackPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL48361, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6380, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Dabigatran
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Dabigatran
- ChEMBL
- CHEMBL48361
- DrugBank
- DB14726
- PubChem CID
- 216210
- CAS number
- 211914-51-1
- FDA UNII
- I0VM4M70GC
- Wikidata
- Q419345
- Wikipedia
- Dabigatran
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Dabigatran
11 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Dabigatran
23 conditionsAll 23 conditions
| Condition (as registered) | Trials |
|---|---|
| Stroke | 3 |
| Atrial Fibrillation | 3 |
| Ischemic Stroke | 2 |
| Healthy Male Participants | 1 |
| Portal Vein Thrombosis | 1 |
| Liver Cirrhosis | 1 |
| Pulmonary Embolism | 1 |
| Venous Thromboembolism | 1 |
| Large-Artery Atherosclerosis (Embolus/Thrombosis) | 1 |
| Bleeding Post Cardiac Surgery | 1 |
| Indication for Anticoagulation | 1 |
| Antiphospholipid Syndrome | 1 |
| Thrombosis | 1 |
| Anticoagulants Causing Adverse Effects in Therapeutic Use | 1 |
| Cerebral Infarction | 1 |
| Aortic Valve Stenosis | 1 |
| Cardiovascular Diseases | 1 |
| Heart Diseases | 1 |
| Heart Valve Diseases | 1 |
| Staphylococcus Aureus Endocarditis | 1 |
| Staphylococcus Aureus Septicemia | 1 |
| Staphylococcus Aureus Bacteremia | 1 |
| Staphylococcus Aureus Bloodstream Infection | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Dabigatran trials
How many clinical trials are testing Dabigatran?
11 current trials in our Germany, Denmark, Canada, India, Sweden, Australia, China, France, USA, Spain, Italy, Netherlands, Switzerland, Brazil, South Korea and Norway registers name Dabigatran (also registered as SUB20521) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Dabigatran trials recruiting patients?
Yes. 8 of the 11 trials are recruiting: 3 with sites in Germany, 2 with sites in Denmark, 3 with sites in Canada, 1 with sites in India, 2 with sites in Sweden, 2 with sites in Australia, 1 with sites in China, 2 with sites in France, 1 with sites in USA, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Netherlands, 1 with sites in Switzerland, 1 with sites in Brazil, 1 with sites in South Korea and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Dabigatran clinical trials?
Population Health Research Institute (2), Deciphera Pharmaceuticals, LLC (1), Institute of Liver and Biliary Sciences, India (1) and Nanjing First Hospital, Nanjing Medical University (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dabigatran works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dabigatran works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dabigatran (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.